Medpace Holdings, CEO August J. Troendle Sells 49,347 Shares of Stock
June 16, 2023
☀️Trending News
Medpace Holdings ($NASDAQ:MEDP), Inc. is a leading global clinical contract research organization providing personalized therapeutic development services to the biopharmaceutical industry. This stock sale was completed on the same day and totaled over $2 million. The sale of shares was disclosed in a filing with the Securities and Exchange Commission (SEC). According to the filing, Mr. Troendle disposed of this stock by way of an option exercise. The company offers a wide range of services from preclinical to post-marketing studies for the development of innovative therapies.
Medpace has established itself as an industry leader in personalized medicine, and has become the go-to CRO for many pharmaceutical and biotechnology companies. Mr. Troendle has been involved with Medpace since its inception and currently serves as its CEO. His most recent sale of stock suggests that he may be positioning himself to take further profits from his involvement with the company.
Market Price
At the time of the sale, the stock opened at $219.0 and closed at $218.3, representing a 0.3% decrease from its previous closing price of $219.0. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Medpace Holdings. More…
| Total Revenues | Net Income | Net Margin |
| 1.56k | 256.83 | 16.2% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Medpace Holdings. More…
| Operations | Investing | Financing |
| 421.87 | -37.04 | -416.38 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Medpace Holdings. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 1.4k | 1.05k | 11.28 |
Key Ratios Snapshot
Some of the financial key ratios for Medpace Holdings are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 20.6% | 30.0% | 19.2% |
| FCF Margin | ROE | ROA |
| 24.6% | 51.2% | 13.5% |
Analysis
At GoodWhale, we want to help investors make informed decisions when it comes to investing in MEDPACE HOLDINGS. An analysis of MEDPACE HOLDINGS’s financials by our experts have determined that it is a high-risk investment in terms of financial and business aspects. We have also detected two risk warnings in the income sheet of MEDPACE HOLDINGS. These issues lie outside of the financials and need more attention. To gain further insight into this risk issue, sign up with us now, and check out our detailed analysis. More…
Peers
Medpace’s services include clinical trial management, data management, biostatistics, and medical writing. Medpace’s competitors include Icon PLC, Syneos Health Inc, and IQVIA Holdings Inc.
– Icon PLC ($NASDAQ:ICLR)
Icon PLC is a publicly traded company with a market capitalization of $14.59 billion as of March 2022. The company has a return on equity of 4.28%. Icon is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. The company has a network of over 80 sites in 40 countries. Icon’s services include clinical research, regulatory affairs, quality management, data management, and biostatistics.
– Syneos Health Inc ($NASDAQ:SYNH)
Synoes Health Inc is a pharmaceutical company with a market cap of 4.81B as of 2022. The company has a Return on Equity of 9.89%. The company develops, manufactures, and sells pharmaceutical products. The company’s products include prescription drugs, over-the-counter drugs, and medical devices. The company operates in the United States, Europe, and Asia.
– IQVIA Holdings Inc ($NYSE:IQV)
IQVIA Holdings Inc is a global healthcare company that provides market research, data, and analytics solutions to help customers drive healthcare transformation and growth. The company’s market cap as of 2022 is 33.49B, and its ROE is 19.29%. IQVIA’s customers include healthcare payers and providers, pharmaceutical and biotech companies, and government agencies. The company’s solutions help its customers drive healthcare transformation by improving patient outcomes, reducing costs, and increasing access to care.
Summary
Investing in Medpace Holdings, Inc. (MEDP) has been a profitable endeavor recently. This is in part due to the company’s strong leadership. This further signals positive prospects for MEDP, as Troendle expects further growth for the company.
Analysts suggest that MEDP is an attractive investment opportunity, with its strong foundation and a well-established track record of successful decisions. The potential for long-term gains is significant, and investors should consider the stock for their portfolios.
Related Posts
Recent Posts
